SYDNEY: NeuroScientific Biopharmaceuticals announced the resignation of its CEO and Managing Director, Mr Matt Liddelow effective immediately.
NSB’s Chairman Mr Paul Rennie said, “I would like to acknowledge Mr Liddelow’s service of approximately 4.5 years and thank him for his efforts during that time. The Company will commence a domestic and international search for a new CEO who has pharmaceutical development experience. Together with the senior management team, we will commence a review of operations and make whatever changes we need to make to ensure our lead asset EmtinB continues to progress to commercialisation.
“I was attracted to NSB, and remain excited about the company because of the potential of EmtinB to help people with neurodegenerative diseases. I acknowledge the loss in shareholder value as a result of the rejected Human Research Ethics Committee (HREC) submission and I will work tirelessly with my NSB colleagues to do what we can to get EmtinB into a Phase 1 clinical trial as quickly as possible. A rebuild of the Company is underway and I appreciate the support of all investors who have remained with us. Thank you”.